These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37039113)

  • 21. In an in-vitro model using human fetal membranes, 17-α hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening.
    Kumar D; Moore RM; Mercer BM; Mansour JM; Mesiano S; Schatz F; Lockwood CJ; Moore JJ
    Am J Obstet Gynecol; 2017 Dec; 217(6):695.e1-695.e14. PubMed ID: 29031893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
    Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
    Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolism of 17alpha-hydroxyprogesterone caproate, an agent for preventing preterm birth, by fetal hepatocytes.
    Sharma S; Ellis EC; Dorko K; Zhang S; Mattison DR; Caritis SN; Venkataramanan R; Strom SC
    Drug Metab Dispos; 2010 May; 38(5):723-7. PubMed ID: 20097724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 17-hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model.
    Amaral LM; Cornelius DC; Harmon A; Moseley J; Martin JN; LaMarca B
    Hypertension; 2015 Jan; 65(1):225-31. PubMed ID: 25368030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.
    Hines M; Lyseng-Williamson KA; Deeks ED
    Clin Drug Investig; 2013 Mar; 33(3):223-7. PubMed ID: 23413110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials.
    EPPPIC Group
    Lancet; 2021 Mar; 397(10280):1183-1194. PubMed ID: 33773630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation.
    Caritis SN; Sharma S; Venkataramanan R; Hankins GD; Miodovnik M; Hebert MF; Umans JG; Benedetti T; Mattison D; Zajicek A; Fischer D; Jackson A;
    Am J Obstet Gynecol; 2012 Nov; 207(5):398.e1-8. PubMed ID: 22967833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of oral Dydrogesterone and 17-α hydroxyprogesterone caprate in the prevention of preterm birth.
    Alizadeh F; Mahmoudinia M; Mirteimoori M; Pourali L; Niroumand S
    BMC Pregnancy Childbirth; 2022 Mar; 22(1):167. PubMed ID: 35232423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Qualitative and quantitative measures of various compounded formulations of 17-alpha hydroxyprogesterone caproate.
    Caritis SN; Zhao Y; Bettinger J; Venkataramanan R
    Am J Obstet Gynecol; 2013 Jun; 208(6):470.e1-5. PubMed ID: 23453884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
    Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T
    Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developmental exposure to 17-α-hydroxyprogesterone caproate disrupts decision-making in adult female rats: A potential role for a dopaminergic mechanism.
    Graney PL; Chen MY; Wood RI; Wagner CK
    Horm Behav; 2024 Jul; 163():105550. PubMed ID: 38669977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of endogenous steroid hormones on 17-alpha-hydroxyprogesterone caproate metabolism.
    Cuppett CD; Zhao Y; Caritis S; Zhang S; Zhao W; Venkataramanan R
    Am J Obstet Gynecol; 2013 Jan; 208(1):86.e1-6. PubMed ID: 23063018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does 17-α-hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?
    Mulder EJ; Versteegh EM; Bloemenkamp KW; Lim AC; Mol BW; Bekedam DJ; Kwee A; Bruinse HW; Christiaens GC
    Ultrasound Obstet Gynecol; 2013 Sep; 42(3):329-34. PubMed ID: 23592400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 17-Hydroxyprogesterone caproate improves hypertension and renal endothelin-1 in response to sFlt-1 induced hypertension in pregnant rats.
    Amaral LM; Cottrell JN; Comley KM; Cunningham MW; Witcher A; Vaka VR; Ibrahim T; LaMarca B
    Pregnancy Hypertens; 2020 Oct; 22():151-155. PubMed ID: 32980622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of partial compliance on the prevention of recurrent preterm birth in women receiving weekly 17 alpha-hydroxyprogesterone caproate injections.
    Haidar ZA; Moussa HN; Hosseini Nasab S; Sibai BM
    J Matern Fetal Neonatal Med; 2017 Dec; 30(24):2926-2932. PubMed ID: 27921517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
    Boelig RC; Locci M; Saccone G; Gragnano E; Berghella V
    Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100658. PubMed ID: 35562009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.
    Caritis SN; Sharma S; Venkataramanan R; Rouse DJ; Peaceman AM; Sciscione A; Spong CY; Varner MW; Malone FD; Iams JD; Mercer BM; Thorp JM; Sorokin Y; Carpenter M; Lo J; Ramin S; Harper M;
    Am J Obstet Gynecol; 2011 Jul; 205(1):40.e1-8. PubMed ID: 21620357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
    Nelson DB; McIntire DD; Leveno KJ
    Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.